Please ensure Javascript is enabled for purposes of website accessibility
Home > Products > Antibodies > Invivo Antibodies

InVivoMAb Anti-Campylobacter jejuni subsp. wlaB/pglK Nanobody (Iv0202) (JN929010)

InVivoMAb Anti-Campylobacter jejuni subsp. wlaB/pglK Nanobody (Iv0202)
InVivoMAb Anti-Campylobacter jejuni subsp. wlaB/pglK Nanobody (Iv0202)
Price(USD): $
Spec:
  • 100ug
  • 1mg
Number:
Contact us
  • Overview

  • Images

  • References

  • Datasheet

Overview
Catalog No.JN929010
Description
InVivoMAb Anti-Campylobacter jejuni subsp. wlaB/pglK Nanobody (Iv0202) [Iv0202] (JN929010) is a alpaca monoclonal antibody detecting Protein glycosylation K in ELISA, Neutralization.
Species reactivityCampylobacter jejuni subsp. jejuni serotype O:2 (strain ATCC 700819 / NCTC 11168)
ApplicationsELISA, Neutralization
Host speciesAlpaca
IsotypeVHH-8His-Cys-tag
Clone IDIv0202
Clonality Monoclonal
Target Protein glycosylation K, 7.5.2.5, pglK, wlaB, Cj1130c
Endotoxin level <0.01 EU/ug
Purity >95% as determined by SDS-PAGE.
Purification Purified by Nickel column.
Accession Q0P9C4
RRID InVivoMAb Anti-Campylobacter jejuni subsp. wlaB/pglK Nanobody (Iv0202) (abinScience Cat# JN929010, RRID:AB_3727810)
Form Liquid
Storage buffer 0.01M PBS, pH 7.4.

Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.

Stability and Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Background

Protein glycosylation K (wlaB/pglK) is a ~64 kDa protein. Mediates the ATP-dependent translocation of the undecaprenylpyrophosphate-linked heptasaccharide intermediate across the cell membrane; this is an essential step during the N-linked protein glycosylation pathway. Transport across the membrane is effected via ATP-driven conformation changes. Most likely, only the polar and charged part of the glycolipid enter the substrate-binding cavity, and the lipid tail remains exposed to the membrane lipids during the transmembrane flipping process.

Note For research use only. Not suitable for clinical or therapeutic use.
Images
  • InVivoMAb Anti-Campylobacter jejuni subsp. wlaB/pglK Nanobody (Iv0202)

    SDS-PAGE

    SDS-PAGE for InVivoMAb Anti-Campylobacter jejuni subsp. wlaB/pglK Nanobody (Iv0202).

References
Formula
Mass (g) = Concentration (mol/L) × Volume (L) × MW (g/mol)
Enter any 2 of Mass, Concentration, Volume + Molecular Weight to solve for the unknown.
Mass
=
Concentration
×
Volume
Molecular Weight *
g/mol
Formula
C₁ × V₁ = C₂ × V₂
Enter any 3 of the 4 values to solve for the unknown.
Stock Solution
C₁ (Stock Conc.)
×
V₁ (Stock Vol.)
=
Working Solution
C₂ (Working Conc.)
×
V₂ (Working Vol.)
Recommendation

Contact us for custom quotes, bulk requests and any other issues.

Mail: support@abinScience.com

Distributor list